O	0	5	SCORE
O	6	11	Study
O	12	18	report
O	19	20	1
O	20	21	:
O	22	30	baseline
O	31	43	associations
O	44	51	between
B-Characteristic	52	59	central
I-Characteristic	60	67	retinal
I-Characteristic	68	77	thickness
O	78	81	and
B-Characteristic	82	88	visual
I-Characteristic	89	95	acuity
O	96	98	in
O	99	107	patients
O	108	112	with
B-Disease	113	120	retinal
I-Disease	121	125	vein
I-Disease	126	135	occlusion
O	135	136	.

O	138	140	To
O	141	152	investigate
O	153	156	the
O	157	169	relationship
O	170	177	between
O	178	186	baseline
B-Characteristic	187	193	center
I-Characteristic	194	199	point
I-Characteristic	200	207	retinal
I-Characteristic	208	217	thickness
O	218	226	measured
O	227	229	by
B-Diagnostic_tool	230	237	optical
I-Diagnostic_tool	238	247	coherence
I-Diagnostic_tool	248	258	tomography
O	259	260	(
B-Diagnostic_tool	260	263	OCT
O	263	264	)
O	265	268	and
B-Characteristic	269	273	best
I-Characteristic	273	274	-
I-Characteristic	274	283	corrected
I-Characteristic	284	290	visual
I-Characteristic	291	297	acuity
O	298	300	in
B-Anatomy	301	305	eyes
O	306	310	with
B-Symptom	311	318	macular
I-Symptom	319	324	edema
O	325	335	associated
O	336	340	with
B-Disease	341	348	retinal
I-Disease	349	353	vein
I-Disease	354	363	occlusion
O	364	367	and
O	368	370	to
O	371	382	investigate
O	383	388	other
O	389	396	factors
O	397	407	associated
O	408	412	with
O	413	421	baseline
B-Characteristic	422	428	visual
I-Characteristic	429	435	acuity
I-Characteristic	436	442	letter
I-Characteristic	443	448	score
O	448	449	.

O	450	453	The
O	454	462	Standard
O	463	467	Care
O	468	474	versus
O	475	489	COrticosteroid
O	490	493	for
B-Disease	494	501	REtinal
I-Disease	502	506	Vein
I-Disease	507	516	Occlusion
O	517	518	(
O	518	523	SCORE
O	523	524	)
O	525	530	Study
O	531	539	includes
O	540	541	2
O	542	553	multicenter
O	553	554	,
O	555	565	randomized
O	566	574	clinical
O	575	581	trials
O	581	582	:
O	583	586	one
O	587	597	evaluating
O	598	610	participants
O	611	615	with
B-Disease	616	623	central
I-Disease	624	631	retinal
I-Disease	632	636	vein
I-Disease	637	646	occlusion
O	647	648	(
B-Disease	648	652	CRVO
O	652	653	)
O	654	657	and
O	658	661	the
O	662	667	other
O	668	678	evaluating
O	679	691	participants
O	692	696	with
B-Disease	697	703	branch
I-Disease	704	711	retinal
I-Disease	712	716	vein
I-Disease	717	726	occlusion
O	727	728	(
B-Disease	728	732	BRVO
O	732	733	)
O	733	734	.

O	735	740	After
O	741	749	omitting
O	750	752	17
O	753	765	participants
O	766	770	with
O	771	778	missing
O	779	781	or
O	782	792	unreliable
B-Diagnostic_tool	793	796	OCT
O	797	809	measurements
O	809	810	,
O	811	819	analyses
O	820	829	proceeded
O	830	834	with
O	835	838	665
O	839	847	enrolled
O	848	853	SCORE
O	854	859	Study
O	860	872	participants
O	873	874	(
O	874	877	665
B-Anatomy	878	882	eyes
O	882	883	)
O	883	884	,
O	885	894	including
O	895	898	262
O	899	903	with
B-Disease	904	908	CRVO
O	909	912	and
O	913	916	403
O	917	921	with
B-Disease	922	926	BRVO
O	926	927	.

O	928	930	At
O	931	939	baseline
O	939	940	,
B-Characteristic	941	947	center
I-Characteristic	948	953	point
I-Characteristic	954	963	thickness
O	964	967	was
O	968	976	measured
O	977	979	by
B-Diagnostic_tool	980	983	OCT
O	984	985	(
B-Diagnostic_tool	985	992	Stratus
I-Diagnostic_tool	993	996	OCT
I-Diagnostic_tool	997	998	3
O	999	1000	[
O	1000	1001	n
O	1001	1002	=
O	1002	1005	663
O	1005	1006	]
O	1007	1010	and
B-Diagnostic_tool	1011	1015	OCT2
O	1016	1017	[
O	1017	1018	n
O	1018	1019	=
O	1019	1020	2
O	1020	1021	]
O	1022	1023	;
O	1024	1028	Carl
O	1029	1034	Zeiss
O	1035	1043	Meditech
O	1043	1044	,
O	1045	1051	Dublin
O	1051	1052	,
O	1053	1055	CA
O	1055	1056	)
O	1056	1057	,
O	1058	1061	and
B-Characteristic	1062	1068	visual
I-Characteristic	1069	1075	acuity
O	1076	1079	was
O	1080	1088	measured
O	1089	1091	by
O	1092	1095	the
O	1096	1106	electronic
O	1107	1112	Early
O	1113	1122	Treatment
B-Disease	1123	1131	Diabetic
I-Disease	1132	1143	Retinopathy
O	1144	1149	Study
O	1150	1151	(
O	1151	1152	E
O	1152	1153	-
O	1153	1158	ETDRS
O	1158	1159	)
O	1160	1171	methodology
O	1171	1172	.

B-Characteristic	1173	1179	Center
I-Characteristic	1180	1185	point
I-Characteristic	1186	1195	thickness
O	1196	1199	and
B-Characteristic	1200	1204	best
I-Characteristic	1204	1205	-
I-Characteristic	1205	1214	corrected
I-Characteristic	1215	1216	E
I-Characteristic	1216	1217	-
I-Characteristic	1217	1222	ETDRS
I-Characteristic	1223	1229	visual
I-Characteristic	1230	1236	acuity
I-Characteristic	1237	1243	letter
I-Characteristic	1244	1249	score
O	1249	1250	.

O	1251	1254	The
O	1255	1266	correlation
O	1267	1278	coefficient
O	1279	1282	for
O	1283	1286	the
O	1287	1298	association
O	1299	1306	between
O	1307	1315	baseline
B-Diagnostic_tool	1316	1319	OCT
O	1319	1320	-
O	1320	1328	measured
B-Characteristic	1329	1335	center
I-Characteristic	1336	1341	point
I-Characteristic	1342	1351	thickness
O	1352	1355	and
B-Characteristic	1356	1360	best
I-Characteristic	1360	1361	-
I-Characteristic	1361	1370	corrected
I-Characteristic	1371	1372	E
I-Characteristic	1372	1373	-
I-Characteristic	1373	1378	ETDRS
I-Characteristic	1379	1385	visual
I-Characteristic	1386	1392	acuity
I-Characteristic	1393	1399	letter
I-Characteristic	1400	1405	score
O	1406	1408	is
O	1409	1410	-
O	1410	1411	0
O	1411	1412	.
O	1412	1414	27
O	1415	1416	(
O	1416	1418	95
O	1418	1419	%
O	1420	1430	confidence
O	1431	1436	limit
O	1436	1437	:
O	1438	1439	-
O	1439	1440	0
O	1440	1441	.
O	1441	1443	38
O	1444	1446	to
O	1447	1448	-
O	1448	1449	0
O	1449	1450	.
O	1450	1452	16
O	1452	1453	)
O	1454	1457	for
O	1458	1470	participants
O	1471	1473	in
O	1474	1477	the
B-Disease	1478	1482	CRVO
O	1483	1488	trial
O	1489	1492	and
O	1493	1494	-
O	1494	1495	0
O	1495	1496	.
O	1496	1498	28
O	1499	1500	(
O	1500	1502	95
O	1502	1503	%
O	1504	1514	confidence
O	1515	1520	limit
O	1520	1521	:
O	1522	1523	-
O	1523	1524	0
O	1524	1525	.
O	1525	1527	37
O	1528	1530	to
O	1531	1532	-
O	1532	1533	0
O	1533	1534	.
O	1534	1536	19
O	1536	1537	)
O	1538	1540	in
O	1541	1544	the
B-Disease	1545	1549	BRVO
O	1550	1555	trial
O	1555	1556	.

O	1557	1567	Regression
O	1568	1576	modeling
O	1577	1586	estimated
O	1587	1590	the
O	1591	1600	following
O	1601	1609	decrease
O	1610	1612	in
O	1613	1621	baseline
B-Characteristic	1622	1628	visual
I-Characteristic	1629	1635	acuity
I-Characteristic	1636	1642	letter
I-Characteristic	1643	1648	score
O	1649	1652	for
O	1653	1658	every
O	1659	1662	100
O	1662	1663	-
O	1663	1669	microm
O	1670	1678	increase
O	1679	1681	in
B-Characteristic	1682	1685	OCT
I-Characteristic	1685	1686	-
I-Characteristic	1686	1694	measured
I-Characteristic	1695	1701	center
I-Characteristic	1702	1707	point
I-Characteristic	1708	1717	thickness
O	1717	1718	:
O	1719	1720	1
O	1720	1721	.
O	1721	1722	7
O	1723	1730	letters
O	1731	1732	(
O	1732	1733	P
O	1733	1734	=
O	1734	1735	0
O	1735	1736	.
O	1736	1740	0007
O	1740	1741	)
O	1742	1745	for
B-Disease	1746	1750	CRVO
O	1751	1754	and
O	1755	1756	1
O	1756	1757	.
O	1757	1758	9
O	1759	1766	letters
O	1767	1768	(
O	1768	1769	P
O	1770	1771	<
O	1772	1773	0
O	1773	1774	.
O	1774	1778	0001
O	1778	1779	)
O	1780	1783	for
B-Disease	1784	1788	BRVO
O	1788	1789	.

O	1790	1792	On
O	1793	1796	the
O	1797	1802	basis
O	1803	1805	of
O	1806	1818	multivariate
O	1819	1829	regression
O	1830	1836	models
O	1836	1837	,
O	1838	1846	baseline
O	1847	1854	factors
O	1855	1868	significantly
O	1869	1879	associated
O	1880	1881	(
O	1881	1882	P
O	1883	1884	<
O	1885	1886	0
O	1886	1887	.
O	1887	1889	05
O	1889	1890	,
O	1891	1896	after
O	1897	1906	adjusting
O	1907	1910	for
O	1911	1919	multiple
O	1920	1927	testing
O	1927	1928	)
O	1929	1933	with
O	1934	1942	baseline
B-Characteristic	1943	1949	visual
I-Characteristic	1950	1956	acuity
I-Characteristic	1957	1963	letter
I-Characteristic	1964	1969	score
O	1970	1977	include
B-Characteristic	1978	1981	age
O	1982	1985	and
B-Characteristic	1986	1994	duration
I-Characteristic	1995	1997	of
I-Characteristic	1998	2005	macular
I-Characteristic	2006	2011	edema
O	2012	2015	for
B-Disease	2016	2020	CRVO
O	2021	2033	participants
O	2034	2037	and
B-Characteristic	2038	2044	center
I-Characteristic	2045	2050	point
I-Characteristic	2051	2060	thickness
O	2061	2064	and
O	2065	2073	presence
O	2074	2076	of
B-Symptom	2077	2084	cystoid
I-Symptom	2085	2091	spaces
O	2092	2095	for
B-Disease	2096	2100	BRVO
O	2101	2113	participants
O	2113	2114	.

O	2115	2118	The
O	2119	2130	correlation
O	2131	2138	between
B-Characteristic	2139	2142	OCT
I-Characteristic	2142	2143	-
I-Characteristic	2143	2151	measured
I-Characteristic	2152	2158	center
I-Characteristic	2159	2164	point
I-Characteristic	2165	2174	thickness
O	2175	2178	and
B-Characteristic	2179	2185	visual
I-Characteristic	2186	2192	acuity
I-Characteristic	2193	2199	letter
I-Characteristic	2200	2205	score
O	2206	2208	is
O	2209	2215	modest
O	2215	2216	.

B-Characteristic	2217	2220	OCT
I-Characteristic	2220	2221	-
I-Characteristic	2221	2229	measured
I-Characteristic	2230	2236	center
I-Characteristic	2237	2242	point
I-Characteristic	2243	2252	thickness
O	2253	2263	represents
O	2264	2265	a
O	2266	2272	useful
O	2273	2277	tool
O	2278	2281	for
O	2282	2285	the
O	2286	2295	detection
O	2296	2299	and
O	2300	2310	monitoring
O	2311	2313	of
B-Symptom	2314	2321	macular
I-Symptom	2322	2327	edema
O	2328	2330	in
B-Disease	2331	2338	retinal
I-Disease	2339	2343	vein
I-Disease	2344	2353	occlusion
O	2353	2354	,
O	2355	2358	but
O	2359	2361	it
O	2362	2368	cannot
O	2369	2377	reliably
O	2378	2388	substitute
O	2389	2392	for
B-Characteristic	2393	2399	visual
I-Characteristic	2400	2406	acuity
O	2407	2419	measurements
O	2419	2420	.
